查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲基因组癌症面板和分析市场：分析和预测（2023-2033）
市场调查报告书
商品编码
1408631

欧洲基因组癌症面板和分析市场：分析和预测（2023-2033）

Europe Genomic Cancer Panel and Profiling Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 92 Pages | 商品交期: 1-5个工作天内

价格

截至2023年，欧洲基因组癌症面板和分析市场规模为26.4亿美元，预计2033年将达到65亿美元。

2023-2033年预测期间的复合年增长率预计为9.42%。这种增长是由基因组研究的进步和对肿瘤学精准治疗的日益重视所推动的。

主要市场统计数据
预测期 2023-2033
2023年评估 26.4亿美元
2033年预测 65亿美元
复合年增长率 9.42%

基因组癌症组合和分析是癌症检测的现代方法，可在症状出现之前检查恶性的遗传特征。一个主要优点是这些面板可以提供广泛的遗传见解，促进早期检测并促进客製化治疗策略的发展。基因组癌症面板和分析市场正在扩大，因为这些技术具有改变癌症管理的变革潜力。这些面板允许医疗保健提供者识别特定的基因变化并相应地定制干预措施，从而提高我们对癌症遗传学的理解。

在欧洲市场，基因癌症检测和分析在癌症筛检和管理方面越来越受欢迎。这些尖端技术提供了有关恶性的详细遗传资讯，从而可以进行早期检测和个性化治疗方法。这些面板的需求不断增加，因为它们具有改变癌症管理的潜力。促进欧洲市场扩张的因素包括液体活检检测的普及、生活方式改变导致的癌症风险增加以及早期检测的需要。

该报告研究了欧洲基因组癌症面板和分析市场，并提供了市场概述，包括按应用、最终用户、国家和进入市场的公司概况分類的趋势。

目录

执行摘要

第一章 市场

  • 市场范围
  • 调查方法
  • 市场概况

第二章 产业分析

  • 法律要求
  • 专利分析

第三章市场动态

  • 概述
    • 影响分析
  • 市场驱动因素
  • 市场抑制因素
  • 市场机会

第四章竞争考察

  • 概述
  • 关键策略和发展
  • 成长份额分析

第五章 按地区划分

  • 概述
  • 欧洲
    • 关键动态
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他地区

第六章 公司简介

  • F. Hoffmann-La Roche Ltd
Product Code: BHP1775SS

“The Europe Genomic Cancer Panel and Profiling Market Expected to Reach $6.50 Billion by 2033.”

Introduction to Europe Genomic Cancer Panel and Profiling Market

As of 2023, the Europe genomic cancer panel and profiling market was valued at $2.64 billion and is expected to attain a value of $6.50 billion in 2033. The market is anticipated to grow at a CAGR of 9.42% during the forecast period 2023-2033. This growth is being driven by advances in genomic research and an increasing emphasis on precision therapy in oncology.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$2.64 Billion
2033 Forecast$6.50 Billion
CAGR9.42%

Market Introduction

Genomic cancer panels and profiling are a contemporary technique to cancer detection that examines the genetic characteristics of malignancies before symptoms occur. The capacity of these panels to provide extensive genetic insights facilitates early detection and the development of tailored treatment strategies, which is a considerable advantage. The genomic cancer panel and profiling market is expanding because to the transformational potential these technologies have for changing cancer management. These panels improve our understanding of cancer genetics by allowing healthcare providers to identify particular genetic changes and customize interventions accordingly.

In the European market, genetic cancer panels and profiling are gaining popularity for cancer screening and management. These modern technologies provide detailed genetic information about malignancies, allowing for early detection and individualized treatment regimens. The demand for these panels is increasing as a result of their transformational potential in changing cancer management. Factors driving market expansion in Europe include the growing popularity of liquid biopsy testing, increased cancer risk due to lifestyle changes, and the need for early detection.

Market Segmentation

Segmentation 1: by Application

  • Clinical
  • Research

Segmentation 2: by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutes
  • Other End Users

Segmentation 3: by Country

  • U.K.
  • France
  • Italy
  • Germany
  • Spain

How can this report add value to an organization?

Product/Innovation Strategy: The Europe genomic cancer panel and profiling market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Market Scope
    • 1.1.1. Key Questions Answered in this Report
  • 1.2. Research Methodology
    • 1.2.1. Genomic Cancer Panel and Profiling Market: Research Methodology
    • 1.2.2. Data Sources
    • 1.2.3. Market Estimation Model
    • 1.2.4. Criteria for Company Profiling
  • 1.3. Market Overview
    • 1.3.1. Market Definition
    • 1.3.2. Market Footprint and Growth Potential
    • 1.3.3. Future Potential

2. Industry Analysis

  • 2.1. Legal Requirements
    • 2.1.1. Regulation of Genetic Tests
    • 2.1.2. NCCN Guidelines
    • 2.1.3. Reimbursement Scenario
  • 2.2. Patent Analysis
    • 2.2.1. Patent Filing Trend
    • 2.2.2. Patent Analysis (by Year)
    • 2.2.3. Patent Analysis (by Country)

3. Market Dynamics

  • 3.1. Overview
    • 3.1.1. Impact Analysis
  • 3.2. Market Drivers
    • 3.2.1. Rising Need for Cancer Profiling in Developed Countries Driving Demand for Genomic Panels and Profiling Tests
    • 3.2.2. Increase in Genomic Research Funding Expanding the Market for Genomic Cancer Panels and Profiling
    • 3.2.3. Technological Advancements in the Field of Informatics Expanding Consumer Reach
  • 3.3. Market Restraints
    • 3.3.1. Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market
    • 3.3.2. Impact of High-Cost Pressure Hindering Development in Genomic Cancer Panel and Profiling Testing
  • 3.4. Market Opportunities
    • 3.4.1. Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis
    • 3.4.2. Discovery of New Biomarkers Presents an Opportunity for the Development of Diagnostics Tools and Technologies

4. Competitive Insights

  • 4.1. Overview
  • 4.2. Key Strategies and Developments
    • 4.2.1. Product Launches, Approvals, and Upgradations
    • 4.2.2. Synergistic Activities
    • 4.2.3. Mergers and Acquisitions
    • 4.2.4. Business Expansions, Funding, and Licenses
  • 4.3. Growth-Share Analysis
    • 4.3.1. Growth-Share Analysis (by Technology), 2022

5. By Region

  • 5.1. Overview
  • 5.2. Europe
    • 5.2.1. Key Dynamics
    • 5.2.2. Germany
    • 5.2.3. France
    • 5.2.4. U.K.
    • 5.2.5. Italy
    • 5.2.6. Spain
    • 5.2.7. Rest-of-Europe

6. Company Profiles

  • 6.1. Overview
  • 6.2. F. Hoffmann-La Roche Ltd
    • 6.2.1. Company Overview
    • 6.2.2. Role of F. Hoffmann-La Roche Ltd in the Genomic Cancer Panel and Profiling Market
    • 6.2.3. Corporate Strategies
    • 6.2.4. Business Strategies
    • 6.2.5. Financials
    • 6.2.6. Analyst Perspective

List of Figures

  • Figure 1: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 2: Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
  • Figure 3: Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
  • Figure 4: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
  • Figure 5: Genomic Cancer Panel and Profiling Market: Research Methodology
  • Figure 6: Primary Research Methodology
  • Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 8: Top-Down Approach (Segment-Wise Analysis)
  • Figure 9: Genomic Cancer Panel and Profiling Workflow, End User Perspective
  • Figure 10: Genomic Cancer Panel and Profiling Workflow, Laboratory Technician Perspective
  • Figure 11: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 12: General Testing Criterion According to the NCCN Guidelines
  • Figure 13: Reimbursement Components in the U.S.
  • Figure 14: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Year), January 2020-October 2023
  • Figure 15: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Country), January 2020-October 2023
  • Figure 16: Genomic Cancer Panel and Profiling Market Dynamics
  • Figure 17: Cancer Profiling Cases in Developed Countries
  • Figure 18: Share of Global Cancer Prevalence, 2010-2019
  • Figure 19: Share of Global Age-Standardized Death Rate of Cancer, 2010-2019
  • Figure 20: Genomic Research Funding by National Human Genome Research Institute (NHGRI), $Million, 2020, 2021, and 2022
  • Figure 21: Key Players Offering
  • Figure 22: Reimbursement Reductions Adopted for Oncology Testing as per PAMA Revisions
  • Figure 23: Cost Difference between the Multi-Gene Panel Test and Usual Care Screening Test
  • Figure 24: Share of Key Developments, January 2020-October 2023
  • Figure 25: Number of Product Launches, Approvals, and Upgradations (by Company), January 2020-October 2023
  • Figure 26: Growth-Share Analysis of the Genomic Cancer Panel and Profiling Market (by Technology), 2022
  • Figure 27: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
  • Figure 28: Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 29: Europe Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
  • Figure 30: Europe Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
  • Figure 31: Europe Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
  • Figure 32: Germany Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 33: France Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 34: U.K. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 35: Italy Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 36: Spain Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 37: Rest-of-Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 38: Genomic Cancer Panel and Profiling Market, Total Number of Companies Profiled
  • Figure 39: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 40: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 41: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 42: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Genomic Cancer Panel and Profiling Market, Impact Analysis
  • Table 2: Technological Trends in the Genomic Cancer Panel and Profiling Market
  • Table 3: Genomic Cancer Panel and Profiling Market, Impact Analysis
  • Table 4: Genomic Cancer Panel and Profiling Market, Pipeline Tests
  • Table 5: Ongoing Cancer-Based Biomarkers Trials
  • Table 6: Europe Genomic Cancer Panel and Profiling Market, Impact Analysis